Table 9.

Efficacy and safety of NOACs in patients with CKD.

	Primary efficacy endpoint (%/y)a				Primary safety endpoint (%/y)b
RE-LY
eGFR (mL/min)	<50	50 to<80	≥80	P (int)	<50	50 to <80	≥80	P (int)
Dabi 150	1.53	1.25	0.71		5.50	3.35	2.04
Dabi 110	2.32	1.69	0.88		5.45	2.84	1.48
Warfarin	2.70	1.83	1.05		5.49	3.70	2.43
HR (95% CI)
Dabi 150/W	0.56	0.68	0.67	0.7522	1.01	0.91	0.84	0.6393
	(0.37–0.85)	(0.50–0.92)	(0.42–1.09)		(0.79–1.30)	(0.75–1.11)	(0.62–1.13)
Dabi 110/W	0.85	0.93	0.84	0.9108	0.99	0.76	0.61	0.0607
	(0.59–1.24)	(0.70–1.23)	(0.54–1.32)		(0.77–1.28)	(0.62–0.94)	(0.44–0.84
ROCKET AF
CrCl (mL/min)	30–49	≥50			30–49	≥50
Riva 15	2.32				17.82
Riva 20		1.57				14.24
Warfarin	2.77	2.00			18.28	13.67
HR (95% CI)
Riva/W	0.84 (0.57–1.23)	0.78		0.76	0.98	1.04		0.4496
		(0.63–0.98)			(0.84–1.14)	(0.96–1.13)
ARISTOTLE
eGFR (mL/min)	≤50	>50–80	>80		≤50	>50–80	>80
Api 5	2.11	1.24	0.99		3.21	2.45	1.46
Warfarin	2.67	1.69	1.12		6.44	3.21	1.84
HR (95% CI)
Api/W	0.79	0.74	0.88	0.705	0.50	0.77	0.80	0.030
	(0.55–1.14)	(0.56–0.97)	(0.64–1.22)		(0.38–0.66)	(0.62–0.94)	(0.61–1.04)
ENGAGE AF
CrCl (mL/min)	30–50	>50			30–50	>50
HDER 60/30	2.3	1.4			4.0	2.5
Warfarin	2.7	1.6			5.3	3.1
HR
HDER/W	0.87	0.87		0.94	0.76	0.82		0.62
	(0.65–1.18)	(0.72–1.04)			(0.58–0.98)	(0.71–0.95)

Api: apixaban; CI: confidence interval; CKD: chronic kidney disease; CrCl: creatinine clearance; Dabi: dabigatran; eGFR: estimated glomerular filtration rate; HDER: high-dose edoxaban regimen; HR: hazard ratio: Int: interaction; NOACs: non-vitamin K antagonists; Riva: rivaroxaban; W: warfarin

^aStroke and systemic embolization events;

^bMajor bleeding.